



Company Information Center

August 31, 2005 US Eastern Time zone

**VERTEBRON™ INC. PROUDLY ANNOUNCES ITS FIRST EUROPEAN SPINAL SURGERIES FOLLOWING ITS CE MARKING AND ISO CERTIFICATION**

STRATFORD, Conn.—August 31, 2005—VERTEBRON Inc. (VERTEBRON) is proud to announce its first European spinal surgeries with its Pedicle Screw System (PSS) within Clinique Saint Michel in Brussels, Belgium. Although the first international surgeries were successfully conducted in August, 2004 within South Africa, this recent entry into the European marketplace establishes a significant milestone for VERTEBRON's expanded global presence within Canada, Australia and other international markets. VERTEBRON recently received its CE marking and ISO 13485 certification for its fusion based systems, including the PSS Pedicle Screw and SCP Semi-Constrained Cervical Plate systems. In addition to further bolstering worldwide sales, these critical milestones also advance the introduction and clinical evaluation of VERTEBRON's Cervical Motion Preservation (CMP) Device within international centers.

Dr. Frank Cauwenbergs of Clinique Saint Michel in Brussels, Belgium used the VERTEBRON PSS system in several surgeries last week and commented, "I was most impressed with the VERTEBRON Pedicle Screw System's simplicity and ease of use, especially with its unique locking cap mechanism. We have just completed our first few surgeries with the PSS last week, which performed very well in surgery with minimal training. The innovative PSS system required only a few instruments for the entire procedure. It was also cleverly designed to fit within a single sterilization tray along with the implants which made it very easy for my staff to handle. We look forward to using more of the VERTEBRON PSS system in our upcoming cases and taking even greater advantage of its operative time savings offered through its implant designs' and instrument case layout."

Hosam Afifi, President and CEO for VERTEBRON added, "VERTEBRON is continuing to make significant gains worldwide with both our Pedicle Screw and Cervical Plate Systems, and now also within Europe given our recent CE and ISO certifications. Our rapid growth and successes have been directly attributed to our systems' advanced designs which ensure ease of use, in addition to the personal attention we can afford our surgeons, as a smaller and more proactive emerging company. We believe that this strategy will continue fueling our growth within the European and other international markets. To continue driving our successes, VERTEBRON will soon be launching several new key products and line extensions, in both domestic and European markets, in addition to initiating our CMP clinical trials next year. We are hopeful that these initial European fusion procedures will help further accelerate our CMP artificial disc introduction and its international clinical evaluations."

VERTEBRON is a privately-held, medical device company that has developed spinal implants, including artificial discs (motion preservation), cervical plates, pedicle screws and interbody fusion systems which integrate spinal, orthopaedic and total joint technologies. VERTEBRON's advanced spinal motion preservation devices, fusion technologies and breakthrough designs are strategically positioned to establish the company as a leading provider of next-generation spinal implant solutions. VERTEBRON's comprehensive product portfolio offers simplified surgical techniques with enhanced intra-operative flexibility and innovative instrumentation to spinal surgeons worldwide. For more information, please visit [www.VERTEBRON.com](http://www.VERTEBRON.com).

Any statements in this press release about future expectations, plans and prospects for the Company, including statements containing the words "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, risks and uncertainties. These statements are subject to change based on risks detailed from time to time in VERTEBRON's Business Plan and other documents and other known and unknown risks and factors, which could cause the actual results or performance to differ materially from the statements made. Do not place undue reliance on forward-looking statements, which reflect our analysis only and speak only as of the date hereof. Of course, all of VERTEBRON's motion preservation devices will only be released subject to investigational device exemptions or pre-market approval from the FDA.

Contacts: VERTEBRON Inc., Anan Natarajan 203/380-9340